Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
'This is what it's really like to live with HIV'

The number of young men being diagnosed with HIV has doubled in ten years; the number of new diagnoses among gay and bisexual men has reached a record high, according to the most recent data. The virus is rarely out of the news, and yet, because of continuing developments in treatment, few of us understand what life with the condition is like now. Three young men, all diagnosed in their 20s, talk about living with the virus.

Published
10 April 2015
From
Daily Telegraph
‘Medic’ who says he can cure Ebola, Aids and autism with bleach enema is coming to the UK

Jim Humble, who calls himself the Archbishop of the Genesis II Church of Health and Healing, is due to speak at the Spirit of Health conference in Seaford, East Sussex. But campaigners want organisers to prevent him from promoting his goods.

Published
10 April 2015
From
Metro
Women in PrEP trial feared they would have to leave study if they reported low adherence

Post-study interviews and computer questionnaires conducted with former participants in a trial of pre-exposure prophylaxis (PrEP) that reported zero effectiveness show that participants concealed their low adherence to

Published
10 April 2015
By
Gus Cairns
In first human study, new antibody therapy shows promise in suppressing HIV infection

The new study, conducted in Michel Nussenzweig’s Laboratory of Molecular Immunology, finds that administration of a potent antibody, called 3BNC117, can catch HIV off guard and reduce viral loads.

Published
09 April 2015
From
Rockefeller University press release
HIV Treatment Guidelines Nix Atripla as First-Line Therapy

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antiretrovirals.

Published
09 April 2015
From
AIDSMeds
Opioid substitution treatment increases chances that people who inject drugs will have good adherence to HIV therapy

Opioid substitution treatment (OST) increases the chances of people who inject drugs achieving good adherence to highly active antiretroviral therapy (HAART) by 68%, Canadian investigators report in

Published
09 April 2015
By
Michael Carter
Limited Number of Mutations Responsible for Drug-Resistant HIV

"What we are showing is that the rates of transmitted drug-resistant HIV in the low- and middle-income countries most affected by HIV have increased modestly. The rate of increase in sub-Saharan Africa has been low, and an increase has not been detected in south Asia and Southeast Asia. That's good news," said Robert Shafer, M.D., professor of medicine at Stanford and principal investigator on the study.

Published
08 April 2015
From
Genetic Engineering & Biotechnology News
CUREiculum

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research, organizing into a systematic format for ongoing or issue-specific learning. The CUREiculum was developed in a multi-collaboratory process by leading scientists, community educators and various advocacy organizations who recognized the need for increasing literacy in this exciting arena. The tools are designed for community educators, funders, media and other stakeholders. Fifteen key areas of HIV cure research have been developed into free standing modules.

Published
08 April 2015
From
AVAC
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

Published
08 April 2015
From
Gilead press release
Kids Who Start HIV Treatment With Low CD4s Largely Regain Them

HIV-positive children who have low CD4 counts when starting treatment by and large experience a rebound to normal levels of those immune cells. After two years on HIV meds, 92 percent of the children achieved a CD4 count of 500 or above. Just nine children (1 percent) experienced an AIDS-defining illness during treatment. Children starting with fewer than 200 CD4 cells/mm3 took 1.29 years to reach a CD4 count over 500 cells/mm3.

Published
07 April 2015
From
AIDSMeds

Filter by country